Scarlet Therapeutics is developing the novel red blood cell-based therapeutics (tRBCs) generation platform.
Scarlet Therapeutics has raised $4.4M in total funding. The most recent round was Seed. The last funding was announced in May 2026.
Scarlet Therapeutics's investors include Eos, SCVC, Daft Capital, Oshen, Meltwind Advisory.
Scarlet Therapeutics is headquartered in Bristol, United Kingdom.
Scarlet Therapeutics is developing the novel red blood cell-based therapeutics (tRBCs) generation platform.
Scarlet Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Scarlet Therapeutics — Funding & Investors." VCBacked, May 7, 2026, https://www.vcbacked.co/company/scarlet-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Scarlet Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/scarlet-therapeutics
{{cite web |title=Scarlet Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/scarlet-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated